comparemela.com

Rahuls Dalal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Upadacitinib may be better choice vs ustekinumab for UC remission by week 16

Upadacitinib may be better choice vs ustekinumab for UC remission by week 16
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United kingdomBritish columbiaRahuls dalalHeather bieleBymonica stonehillHarvard medical schoolScientific meeting

AxSpA-IBD: AxSpA Remission on TNFi Seen in Half of Patients

Those who had had inflammatory bowel disease for less than 5 years and those taking adalimumab, as opposed to another TNFi, had higher likelihood of reaching axial spondyloarthritis remission.

United statesBoston universityJean liewRahuls dalalSpondyloarthritis researchTreatment networkHarvey bradshaw indexCentaur labsInflammatory bowel diseaseNflammatory bowel disease ibdAnkylosing spondylitisBiologic therapyUlcerative colitisBiosimilar drugsFollow on biologicsCrohns disease

Over Half of Patients With axSpA, IBD Achieved Clinical Remission After 12 Months of TNF Treatment

At the 12-month mark, 52% of patients in the axSpA cohort and 76% of those in the IBD cohort achieved clinical remission.

Rahuls dalalInternational classification of diseasesDigestive disease weekInternational classification

No Extra C Diff Risk Observed With Vedolizumab in Ulcerative Colitis

Retrospective study found no increased risk versus anti-TNF agents, but more research is needed

United statesMercy medical centerUniversity of chicagoZaina hamzaRussell cohenRahuls dalalBincy abrahamMatilda haganUniversity of chicago medicineHarvard medical schoolMedpage todayInflammatory bowel diseasesChicago medicineHouston methodist hospitalInflammatory bowel

vimarsana © 2020. All Rights Reserved.